Search results
Irina SHUBINA, leading researcher | Cited by 219 | | Read 101 publications | Contact Irina SHUBINA
Jul 14, 2021 · Anti-Cancer Potential of Transiently Transfected HER2-Specific Human Mixed CAR-T and NK Cell Populations in Experimental Models: Initial Studies on Fucosylated Chondroitin Sulfate Usage for Safer Treatment. Biomedicines.
Jul 26, 2020 · While the main treatment of the COVID-19 intoxication is focused on neutralizing the excessive inflammatory response, it is worth considering an equally significant problem of the immunosuppressive conditions including immuno-paralysis, which lead to the secondary infection.
- Mikhail Kiselevskiy, Irina Shubina, Irina Chikileva, Suria Sitdikova, Igor Samoylenko, Natalia Anisi...
- 2020
Antiviral Cell Products against COVID-19: Learning Lessons from Previous Research in Anti-Infective Cell-Based Agents. Irina Chikileva, 1,* Irina Shubina, 1 Anzhelika-Mariia Burtseva, 2 Kirill Kirgizov, 3 Nara Stepanyan, 3 Svetlana Varfolomeeva, 3 and Mikhail Kiselevskiy 1. Marjorie Pion, Academic Editor.
- 10.3390/biomedicines10040868
- 2022/04
- Biomedicines. 2022 Apr; 10(4): 868.
Irina Shubina’s Post. Senior strategist with a focus on brand experience and sustainable development. 8mo. In February this year, I found a Peace Research course that perfectly...
Senior Researcher. Russian Cancer Research Center NN Blokhin. Moscow, Russia. Irina Shubina. Overview. Bio. Network 0. Publications 70. Editorial Contributions 0.
Irina Shubina practices in Moscow, Russian Federation. Her top areas of expertise are COVID-19, Bowen's Disease, Squamous Cell Skin Carcinoma, and Graft Versus Host Disease (GvHD). Her clinical research consists of co-authoring 18 peer reviewed articles in the past 15 years.
